The European Union is currently evaluating an experimental vaccine developed by Pfizer to prevent Lyme disease in both children and adults. This marks a significant step forward, as no vaccine currently exists to protect against this bacterial infection transmitted through tick bites. The vaccine is undergoing the authorization process, signaling potential availability in the future. Lyme disease is a growing concern in many parts of Europe and North America, causing a range of symptoms if left untreated. Successful authorization would provide a crucial preventative measure against the illness. The evaluation will assess the vaccine's safety and efficacy before a final decision is made regarding its use within the EU. This potential vaccine represents hope for reducing the incidence of Lyme disease and its associated health complications.